Biocartis Group NV - ESG Rating & Company Profile powered by AI
Comprehensive ESG analysis of Biocartis Group NV can be accessed by registering for free. Alternative companies in the rating industry group for Biocartis Group NV are displayed below. This report of Biocartis Group NV employs data points from across the web and also from available disclosures by Biocartis Group NV.
Biocartis Group NV in the Medical Equipment, Supplies & Distribution industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 2.7, social score of 3.2 and governance score of 8.0.
4.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Bioteque Corp | 8.0 | High |
| 1 | Amplitude Surgical SA | 8.0 | High |
| 175 | Novocure Ltd | 4.7 | High |
| 175 | TELA Bio Inc | 4.7 | High |
| 179 | Biocartis Group NV | 4.6 | High |
| 179 | Neuropace Inc | 4.6 | High |
| 179 | Invacare Corp | 4.6 | High |
| ... | ... | ... | |
| 380 | ZoomMed Inc | 0.0 | Low |
| 380 | iRay Technology Co Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Biocartis Group NV have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Biocartis Group NV disclose current and historical energy intensity?
Sign up for free to unlockDoes Biocartis Group NV report the average age of the workforce?
Sign up for free to unlockDoes Biocartis Group NV reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Biocartis Group NV disclose its ethnicity pay gap?
Sign up for free to unlockDoes Biocartis Group NV disclose cybersecurity risks?
Sign up for free to unlockDoes Biocartis Group NV offer flexible work?
Sign up for free to unlockDoes Biocartis Group NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Biocartis Group NV disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Biocartis Group NV conduct supply chain audits?
Sign up for free to unlockDoes Biocartis Group NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Biocartis Group NV conduct 360 degree staff reviews?
Sign up for free to unlockDoes Biocartis Group NV disclose the individual responsible for D&I?
Sign up for free to unlockDoes Biocartis Group NV disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Biocartis Group NV disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Biocartis Group NV disclose water use targets?
Sign up for free to unlockDoes Biocartis Group NV have careers partnerships with academic institutions?
Sign up for free to unlockDid Biocartis Group NV have a product recall in the last two years?
Sign up for free to unlockDoes Biocartis Group NV disclose incidents of discrimination?
Sign up for free to unlockDoes Biocartis Group NV allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Biocartis Group NV issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Biocartis Group NV disclose parental leave metrics?
Sign up for free to unlockDoes Biocartis Group NV disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Biocartis Group NV disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Biocartis Group NV disclose the pay ratio of women to men?
Sign up for free to unlockDoes Biocartis Group NV support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Biocartis Group NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Biocartis Group NV reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Biocartis Group NV involved in embryonic stem cell research?
Sign up for free to unlockDoes Biocartis Group NV disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Biocartis Group NV disclose its waste policy?
Sign up for free to unlockDoes Biocartis Group NV report according to TCFD requirements?
Sign up for free to unlockDoes Biocartis Group NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Biocartis Group NV disclose energy use targets?
Sign up for free to unlockDoes Biocartis Group NV disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Biocartis Group NV have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Biocartis Group NV
These potential risks are based on the size, segment and geographies of the company.
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.